PDS Biotechnology amends $6M promissory note
PDS Biotechnology Corp (PDSB) reports that on August 31, 2026 it entered into a First Amendment to Promissory Note with YA II PN, Ltd., amending a promissory note originally issued on June 15, 2026 with an original principal amount of $6,000,000.
Rhea-AI Filing Summary
PDS Biotechnology Corp (PDSB) reports that on August 31, 2026 it entered into a First Amendment to Promissory Note with YA II PN, Ltd., amending a promissory note originally issued on June 15, 2026 with an original principal amount of $6,000,000.
The amendment document is filed as an exhibit, but the specific modified terms are not described in the body of the report.
Positive
- None.
Negative
- None.
8-K Event Classification
3 items: 1.01, 2.03, 9.01
3 items
Item 1.01
Entry into a Material Definitive Agreement
Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 2.03
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Financial
The company incurred a new significant debt or off-balance-sheet obligation.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Original principal amount of Promissory Note: $6,000,000
Date of First Amendment to Promissory Note: August 31, 2026
Date of original Promissory Note: June 15, 2026
+1 more
4 metrics
Original principal amount of Promissory Note
$6,000,000
Promissory Note issued as of June 15, 2026 in favor of YA II PN, Ltd.
Date of First Amendment to Promissory Note
August 31, 2026
Date the company entered into the First Amendment with YA II PN, Ltd.
Date of original Promissory Note
June 15, 2026
Original issuance date of the $6,000,000 Promissory Note
Common Stock par value
$0.00033 per share
Par value of PDS Biotechnology Corp common stock listed on Nasdaq Capital Market
Key Terms
Promissory Note, Emerging growth company, The Nasdaq Capital Market
3 terms
Promissory Note financial
"which amends that certain Promissory Note made by the Company in favor of the Holder"
A promissory note is a written IOU in which one party promises to pay a specific sum, often with interest, to another party by a set date or on demand. Investors care because it functions like a loan: it creates a legal claim on future cash flows, carries credit and timing risk, and can affect valuation or liquidity—think of it as a formal, tradable promise to be repaid that can be assessed like any other debt investment.
Emerging growth company regulatory
"Emerging growth company Yes No"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
The Nasdaq Capital Market market
"Common Stock, par value $0.00033 per share | PDSB | The Nasdaq Capital Market"
A tier of the Nasdaq stock exchange that hosts smaller or early-stage public companies that meet defined listing standards for size, share price and governance. Think of it as a particular shelf in a store for emerging brands: it gives investors a centralized place to find and trade these stocks while signaling that the companies meet basic regulatory and financial rules. Investors watch it for growth opportunities and higher volatility compared with larger markets.
FAQ
What did PDSB disclose about its debt on August 31, 2026?
PDS Biotechnology Corp entered into a First Amendment to a $6,000,000 Promissory Note with YA II PN, Ltd., modifying a note originally issued on June 15, 2026. The detailed amended terms are contained in the filed exhibit.
What is the size of the promissory note mentioned by PDSB?
The promissory note that PDS Biotechnology Corp amended has an original principal amount of $6,000,000, issued as of June 15, 2026 in favor of YA II PN, Ltd.
Who is the counterparty to PDSB in the promissory note amendment?
The counterparty to PDS Biotechnology Corp in the First Amendment to the Promissory Note is YA II PN, Ltd., identified in the report as the Holder of the note.
When was the original PDSB promissory note issued and when was it amended?
PDS Biotechnology Corp’s original promissory note was issued on June 15, 2026, and the First Amendment to that note was entered into on August 31, 2026.
On which market is PDSB’s common stock listed?
PDS Biotechnology Corp’s common stock, par value $0.00033 per share, trades under the symbol PDSB on The Nasdaq Capital Market.
AI-generated analysis. How Rhea-AI works. Not financial advice.
